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Aims: Ethyl glucuronide (EtG) and fatty acid ethyl esters (FAEES) are non-51 
oxidative metabolites of alcohol that can be detected in conventional and non-52 
conventional biological matrices for longer periods than alcohol. The aim was to 53 
describe the time courses of both biomarkers after ingestion of acute low-54 
moderate doses of ethanol. 55 
Methods: The study design was double-blind, randomized, crossover, and 56 
controlled with placebo. Participants were distributed in three different cohorts: 57 
a) cohort-1: two doses of 18 and 30g of ethanol and placebo were administered 58 
to 12 subjects; b) cohort-2: two doses of 6 and 12g of ethanol and placebo were 59 
administered to 6 subjects; c) cohort-3: two doses of 24 and 42g of ethanol and 60 
placebo were administered to 6 subjects. Each participant received two doses 61 
of ethanol and placebo. Plasma concentrations (0-6h) of ethanol and specific 62 
FAEES (palmitic, stearic, linoleic and oleic acid ethyl esters) and urinary 63 
concentrations of EtG (0-24h) were measured.  64 
Results: A dose-dependent increase in blood ethanol concentrations was 65 
observed. EtG excretion and FAEES plasmatic concentrations showed a 66 
disproportionate increase with the ethanol dose suggesting nonlinearity. Area 67 
under the curve (AUC0-6h) of ethanol concentrations showed a linear trend with 68 
non-oxidative metabolites’ concentrations. 69 
Conclusion: The formation rate of ethanol non-oxidative biomarkers does not 70 
follow a linear trend, explained mainly by a disproportionate increase in AUC0-6h 71 
of ethanol concentrations in relation to dose. This observation should be taken 72 
into account when interpreting results in biological matrices in clinical and 73 
forensic settings.  74 
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Short summary 75 
A double-blind, randomized, crossover, and controlled study was conducted 76 
administering ethanol (6-42g). Ethyl glucuronide (EtG) excretion and fatty acid 77 
ethyl esters (FAEES) plasmatic concentrations showed a disproportionate 78 
increase with the ethanol dose suggesting nonlinearity. This observation should 79 
be taken into account when interpreting biomarker concentrations in clinical 80 
settings.  81 
 82 
Abbreviations 83 
AEAT           acyl-Co/ethanol O-acyl-transferase 84 
ADH             alcohol dehydrogenase;  85 
AUC0-6h        area under the curve from 0 to 6h  86 
Cmax                   maximum concentration 87 
CV               coefficient of variation 88 
ECG            electrocardiogram  89 
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EtG              ethyl glucuronide 91 
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GC/MS         gas chromatography-mass spectrometry  93 
LC/MS         liquid chromatography-mass spectrometry 94 
LLOQ          lower limit of quantification 95 
UGT             UDP-glucuronosyltransferase  96 
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Alcohol is the most worldwide consumed legal drug and alcohol use disorders 101 
are common in modern societies (WHO, 2014). Biomarkers of alcohol 102 
consumption are used to prevent health and social problems related with 103 
alcohol, allowing the identification of subjects at a higher risk of alcohol use 104 
disorders or withdrawal and to assess the efficacy of treatments for alcohol 105 
dependence (Bataille et al., 2003; Kip et al., 2008; Dahl et al., 2011). 106 
The interest in non-oxidative metabolites of alcohol has grown in the last years 107 
due to the lack of accuracy or inadequacy for purpose of previously developed 108 
biomarkers and the possibility to detect them in conventional specimens and 109 
alternative biological matrices (Carbacos et al., 2015)  110 
Ethanol is converted to acetaldehyde by hepatic oxidative metabolism (95-98%) 111 
in a reaction regulated by class I isozymes of alcohol dehydrogenase (ADH) 112 
and highly inducible microsomal CYP2E1. In turn acetaldehyde is converted in 113 
acetic acid (acetate) by acetaldehyde dehydrogenase. Only a small fraction of 114 
ethanol (2-5%) is excreted unchanged in urine, sweat or exhaled air, or follows 115 
non-oxidative metabolism, leading to minor metabolites such as ethyl 116 
glucuronide (EtG), ethyl sulfate, ethyl phosphate, phosphatidylethanol and fatty 117 
acid ethyl esters (FAEES). 118 
Blood, urine or breath ethanol concentrations are useless biomarkers of 119 
abstinence because ethanol is cleared from the body at a rate of 0.1–0.25 g l−1 120 
h−1 and becomes undetectable in blood in a few hours (Borucki et al., 2005; 121 
Jatlow and O’Malley, 2010). Clearance in heavy drinkers is still faster due to 122 
CYP2E1 induction (Jones, 2008).  123 
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Non-oxidative metabolites have longer biological half-lives than ethanol, 124 
accumulate in tissues after consumption and allow the detection of ethanol 125 
consumption after larger periods of abstinence. The detection window of non-126 
oxidative metabolites may last for several hours up to some days, depending on 127 
the marker and the amount of alcohol ingested.  128 
EtG is produced by UDP glucuronosyltransferase (UGT), it can be detected in 129 
urine up to 80h after ethanol ingestion (Wurst et al., 2003) and does not 130 
accumulate after repeated drinking (Sarkola et al., 2003).  EtS has a similar 131 
excretion profile and can be used for confirmation of EtG tests (Jatlow and 132 
O’Malley, 2010).  133 
In turn FAEES are produced by esterification of fatty acids and ethanol through 134 
FAEES synthase and acyl-Co/ethanol O-acyl-transferase (AEAT) (Treloar et al., 135 
1996). They appear in the serum bound to albumin and in the core of 136 
lipoproteins (Laposata, 1997) and are associated with alcohol organic damage 137 
(Laposata, 1999). FAEES can be detected in blood up to 24 hours after a 138 
drinking intoxication (Doyle et al., 1994), and up to 44h in heavy drinkers 139 
(Borucki et al., 2004).  140 
Direct ingestion of FAEES should be considered as they have been detected in 141 
food, scotch whiskey and non-alcoholic beverages (Goss et al., 1999). 142 
Moreover both FAAE and EtG are also formed endogenously and have been 143 
detected in ethanol abstainers and children. For FAEES a baseline range from 144 
natural human metabolism has been described while EtG could be produced 145 
from ethanol generated by intestinal bacteria (Borucki et al., 2005; Rosano and 146 
Lin, 2008).  147 
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Their monitoring after recent or even single consumption in law enforcement 148 
and forensic cases is common, but their application to clinical settings is still 149 
limited (Jatlow and O’Malley, 2010). EtG is the one with the most opportunities 150 
to be routinely assessed in treatment programs (high sensitivity and specificity, 151 
wide detection period, detection of low doses and availability of enzyme 152 
immunoassay commercial kits [EIA]) (Wurst et al., 2003; Borucki et al., 2005). 153 
Additionally EtG can be used in clinical trials for confirmation of self-reported 154 
alcohol abstinence (Jatlow et al., 2014). 155 
We have identified several experimental studies assessing urine or blood EtG 156 
(Sarkola et al., 2003; Høiseth et al., 2007; Halter et al., 2008; Høiseth et al., 157 
2008) or blood FAEES (Doyle et al., 1994, 1996; Laposata 1997; Schmitt et al., 158 
1997; Soderberg et al., 1999; Dahl et al., 2002; Goll et al., 2002; Best et al; 159 
2003, 2006) detection after administration of one dose of ethanol or a dose 160 
targeted to reach a fixed alcohol concentration. Three studies have described a 161 
dose dependent increase in urinary EtG concentrations after administration of 162 
different doses of ethanol to the same subjects (Rosano and Lin, 2008; Høiseth 163 
et al., 2010; Jatlow et al 2014). A non-randomized study assessed urine EtG 164 
and plasma FAEES simultaneously recommending the use of urine EtG as 165 
marker of recent alcohol intake (Borucki et al., 2005).  166 
However, no randomized studies assessing both biomarkers (EtG and FAEES) 167 
in healthy subjects and covering a dose range compatible with social 168 
consumption of ethanol have been identified.  169 
Our objective was to describe the time course of both biomarkers after ingestion 170 
of low-moderate doses of ethanol trying to avoid potential confounders by 171 




Materials and methods  174 
Participants 175 
The study was conducted in accordance with the Declaration of Helsinki, 176 
approved by the local Research Ethics Committee (Comitè Ètic d’Investigació 177 
Clínica Parc de Salut Mar) and registered (clinical trials.gov:  NCT01788670). 178 
Eligibility criteria required to be healthy subjects with social ethanol 179 
consumption. Exclusion criteria were daily alcohol consumption of >30g or 180 
current or previous ethanol abuse or dependence. All subjects were informed 181 
and signed a consent form before the first study related procedure and were 182 
financially compensated for their participation. 183 
Twenty four male healthy volunteers were included. All of them were 184 
randomized and finished the study. One third of them were smokers and their 185 
average alcohol consumption was 7g a day. The mean age, body weight and 186 
height were 25.8 years (range 20-36), 79.2kg (range 65.4-92.2) and 181 cm 187 
(range 172-189).   188 
Study design and procedures 189 
Participants were distributed in three different cohorts. Design was double-blind, 190 
randomized, crossover, and controlled with placebo. In cohort-1 drinks 191 
containing 18 and 30g of ethanol and placebo were administered to 12 subjects; 192 
in cohort-2 drinks containing 6 and 12g of ethanol and placebo were 193 
administered to 6 subjects and in cohort-3 drinks containing 24 and 42g of 194 
ethanol and placebo were administered to 6 subjects.  195 
Recruitment and sessions took place in the Clinical Research Unit at Hospital 196 
del Mar Medical Research Institute-IMIM. 197 
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Sessions lasted 6h with a minimum wash out period between sessions of at 198 
least three days. Participants on each cohort were randomly assigned by order 199 
of recruitment to one treatment sequence using a balanced 3 x 3 Latin square 200 
design. Allocation for each participant was concealed for all the staff (beverages 201 
were prepared by personnel not involved in the experimental sessions).  202 
Subjects were requested to abstain from ethanol ingestion and use of other 203 
sources of ethanol (hand sanitizers, mouthwashes) three days before each 204 
session. Breath alcohol tests (Dräger Breathalyzer 7410 Plus, Denmark) and 205 
drugs of abuse tests in urine (Instant-View; ASD Inc, Poway, California, US) 206 
were conducted at baseline to confirm abstinence. Xanthine-containing 207 
foods/drinks were prohibited from the day before till 24h after administration. 208 
On each session day an intravenous catheter was inserted into an arm 209 
subcutaneous vein to obtain blood samples. Treatments were administered at 210 
8:30 AM and half cheese sandwich with sunflower oil was provided 2 and 6h 211 
after treatment administration. Additional water was given to volunteers at 2h 212 
(300 mL) and 4h (100 mL) in order to assure urine generation in each time 213 
interval. Participants left the unit 6h after administration after verifying that the 214 
breath alcohol test was negative.  215 
Treatments 216 
Ethanol conditions were obtained mixing ethanol pharmaceutical grade and 217 
lemonade flavored water (Fontvella Sensación sabor limón, Barcelona, Spain). 218 
Placebo contains only lemonade flavored water. The total volume of the 219 
beverages was 150 mL. All the beverages were consumed in fasting conditions, 220 
orally, in opaque recipients, and in 5 minutes. 221 
Blood and urine samples 222 
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Blood samples to determine ethanol and FAEES (palmitic, stearic, oleic and 223 
linoleic acid ethyl esters) in plasma were drawn at pre-dose and at 15, 30, 45 224 
minutes, and 1, 1.5, 2, 3, 4, 6 hours after treatment administration. Urine 225 
samples were collected at baseline and at different interval periods (0-2h, 2-4h, 226 
4-6h, 6-12h, 12-24h) for EtG quantification. Tyrosol and hydroxytyrosol urine 227 
concentrations were also measured in this clinical trial. Their relationship with 228 
ethanol concentrations have been already published in a previous manuscript 229 
(Pérez-Mañá et al., 2015). 230 
Blood (6 mL) was collected in lithium heparin tubes for ethanol analysis. After 231 
centrifugation at 1700g for 10 minutes at 4° C, plasma was transferred to tubes 232 
sealed with a plastic paraffin film and frozen immediately (-20ºC) to avoid 233 
ethanol evaporation. A second collection blood tube (5 mL) containing EDTA 234 
and aprotinin was used for determination of FAEES. It was centrifuged the 235 
same way as above, and plasma was stored frozen (-20ºC) until analysis. 236 
Urine samples were collected in different recipients and the total amount of 237 
urine generated in each time interval was registered. Three aliquots were stored 238 
from each time interval at -20ºC until analysis. 239 
Ethanol and Ethyl glucuronide analysis 240 
DRI® Ethyl Alcohol Assay (Thermo Fisher, Fremont, CA, USA) was used to 241 
analyze concentrations of ethanol in plasma with a cut-off of 10 mg/dL. 242 
Ethyl Glucuronide was measured with liquid chromatography-mass 243 
spectrometry (LC/MS) using a dilute and shoot approach (see Supplementary 244 
materials for further details).  245 
Fatty acid ethyl esters analysis 246 
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FAEES plasma concentrations were analyzed by gas chromatography-mass 247 
spectrometry (GC/MS). The method of analysis was based on a method 248 
previously described (Kulig et al., 2006), with some modifications (see 249 
Supplementary materials section).  250 
Statistical analysis  251 
Sample size was determined for cohort-1 based on the methodology of 252 
bioequivalence studies (10 subjects would be needed considering an alpha risk 253 
of 0.05, a power of 80%, a 30% of variability and an increase in FAEES 254 
concentrations of at least 40% from placebo). 12 subjects participated to 255 
increase power.  256 
Differences from baseline were calculated for FAEES concentrations. For 257 
FAEES and ethanol the following experimental 258 
pharmacokinetic/pharmacodynamic parameters were calculated: peak 259 
concentration (Cmax), the time to reach the maximum concentration (tmax_c) and 260 
the area under the concentration-time curve from 0 to 6h (AUC0-6h). The AUC 261 
values were calculated with the trapezoidal rule. Urinary EtG excretion from 0 to 262 
24h after administration was calculated as the sum of the total amount excreted 263 
during the different collection intervals. 264 
The data of all three cohorts were analyzed together by means of linear mixed 265 
models, which take into account the correlation between values obtained in the 266 
same subjects. The outcomes of interest were introduced in these models as 267 
dependent variables whereas the ethanol dose was introduced as the 268 
independent variable. In the case of the AUC0-6h of ethanol, the FAEES 269 
concentrations and the EtG excretion (0-24h), the relations between the 270 
outcome and the ethanol dose were not always linear. For that reason, log-271 
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transformations of both outcomes and the ethanol dose were also considered 272 
and those models that showed the most adequate fit based on graphical 273 
inspection of the corresponding residual plots were used. The analyses for the 274 
main outcomes were also performed with the weight-adjusted doses (data not 275 
shown). 276 
In addition, Pearson’s correlation coefficient was computed to study the 277 
association between ethanol and the FAEES concentrations (AUC0-6h and Cmax) 278 
and between the ethanol concentrations (AUC0-6h) and the EtG excretion (0-279 
24h).  280 
Results were considered statistically significant at p values <0.05 and the 281 
statistical software package R, version 3.1.1 (R Foundation for Statistical 282 
Computing, Vienna, Austria), was used for the analyses. All analyses were 283 
conducted with all the participants. 284 
 285 
Results  286 
There were no demographic baseline differences among participants in the 287 
three different cohorts. Also no overlap between ethanol doses was observed 288 
when the dose of ethanol was adjusted to weight of individuals. 289 
Ethanol 290 
There were no positive baseline samples for ethanol. Ethanol plasma 291 
concentrations and pharmacokinetic parameters calculated (AUC0-6h, Cmax, tmax) 292 
increased with the ethanol administered dose (see Figure 1). High variation in 293 
ethanol concentrations was found as the coefficient of variation (CV) of the AUC 294 
among individuals with the same dose ranged from 11.6% to 40.2%. 295 
Furthermore a nonlinear relationship was found between AUC of ethanol 296 
13 
 
concentrations and alcohol dose. The relationship was linearized after the log-297 
transformation of both outcomes. As a summary the pharmacokinetic 298 
parameters estimated for each dose of ethanol are presented in Table 1.  299 
Ethyl glucuronide 300 
Concentrations in spot urine samples collected before drinking were below 301 
LLOQ with the exception of 4 samples of 3 different subjects (values between 302 
0.5 and 2.8 µg/ml). EtG was mainly excreted in the period from 0 to 6 hours for 303 
all doses (2-4h for 6 to 30g, 4-6h for 42g), followed by the period from 6 to 12h 304 
and finally by the period from 12 to 24h. EtG recovery (0-24h) showed a dose-305 
dependent relationship with ethanol administered doses. This relationship 306 
follows an exponential trend as it can be seen in Figure 2. The logarithm of the 307 
recovery of EtG increased linearly as a function of the logarithm of the ethanol 308 
dose (log-dose): on average, augmenting the log-dose by one unit, the log-309 
recovery increased by 1.65 units per gram of alcohol (95%-CI: [1.49, 1.82]; 310 
p<0.001). The relative percent (molar equivalent) of ethanol excreted in the 311 
urine as EtG the first 24 hours ranged from 0.004% to 0.031% in our study. The 312 
values also increased with alcohol administered dose (see figure 2). 313 
EtG excretion within individuals was slightly variable (CVs of EtG excretion for 314 
each dose ranged from 21.2%-34.5%).  The correlation between the ethanol 315 
concentrations (AUC0-6h) and the EtG excretion was 0.82 (95%-CI: [0.70, 0.90]; 316 
p<0.001). The relationship between AUC0-6h of ethanol and EtG excretion was 317 
linear. The equation of the linear relationship calculated was the following: EtG 318 
(µmols)=3.09 x AUC0-6h of ethanol (nmol x h /ml)+14.8.  319 
Fatty acid ethyl esters 320 
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Palmitic acid and stearic acid ethyl esters were above LLOQ before ethanol 321 
ingestion in 6 subjects and oleic acid ethyl ester in 2 subjects. For each specific 322 
FAEES, a dose response relationship with ethanol administration was found 323 
(see Figure 3). Linoleic acid ethyl ester concentrations were undetectable for 324 
several subjects and doses (were above LLOQ for one subject with 6 and 12g, 325 
5 subjects with 18g and 24g, 7 subjects with 30g and all subjects of 42g). 326 
FAEES could be detected till 3 hour for doses ≤ 18g and till 6h for higher doses. 327 
The concentrations of palmitic acid ethyl ester were higher than concentrations 328 
of the other FAEES. The model-based estimations of the Cmax of the different 329 
FAAEs are shown in Table 1. In the case of the palmitic, stearic, and oleic acid 330 
ethyl esters, the logarithm of the Cmax increased linearly as a function of the 331 
logarithm of the ethanol dose (log-dose). Augmenting the log-dose by one unit, 332 
the logarithm of the Cmax increased, on average, in 1.06 (95%-CI: 0.88, 1.24]; 333 
p<0.001), 1.14 (95%-CI: [0.93, 1.34]; p<0.001), and 1.46 units (95%-CI: [1.03, 334 
1.89]; p<0.001), for palmitic, stearic, and oleic acid ethyl esters, respectively.  335 
Concerning the AUC0-6h, the lowest range of the CV among individuals taking 336 
the same dose was observed in the case of palmitic acid ethyl ester (13.5% to 337 
37.5%), whereas the highest range was observed in the case of linoleic acid 338 
ethyl ester (67.8% to 245.0%). The logarithm of the AUC0-6h of the different 339 
FAEES increased linearly as a function of the logarithm of the ethanol dose 340 
(log-dose): on average, augmenting the log-dose by one unit, the log-AUC0-6h 341 
increased by 1.69 units (95%-CI: [1.55, 1.83]; p<0.001) for palmitic acid ethyl 342 
ester, by 1.82 units (95%-CI: [1.60, 2.04]; p<0.001)  for stearic acid , and by 343 
2.25 units (95%-CI: [1.84, 2.66]; p<0.001) for oleic acid. Model-based 344 
estimations of the AUC0-6h of the different FAEES are presented in Table 1. 345 
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In the case of linoleic acid ethyl ester pharmacokinetic parameters, all models 346 
fitted showed a statistically significant increase of both measures as a function 347 
of the alcohol dose (p<0.001 in all cases), but none of the model fits was 348 
satisfactory. For this reason, no model-based estimations of both 349 
pharmacokinetic parameters are provided. 350 
For palmitic, stearic and oleic acid ethyl ester median time to reach maximum 351 
concentration was 30 minutes for doses ≤18g, and 1h for higher doses. The 352 
AUC0-6h of the ethanol concentrations in plasma correlated with the AUC0-6h of 353 
the different FAEES (palmitic acid: r=0.87 (95%-CI: [0.78, 0.93]; p<0.001); 354 
stearic acid: r=0.88 ([0.81, 0.94]; p<0.001); oleic acid: r=0.80 ([0.67, 0.87]; 355 
p<0.001); and linoleic acid r=0.65 ([0.45, 0.79; p<0.001])). The relationship 356 
between AUC0-6h of ethanol and AUC0-6h of the different FAEES followed a linear 357 
trend, except for linoleic acid. For the most abundant FAEE after ethanol 358 
ingestion the equation of the linear relationship was: AUC0-6h of palmitic acid 359 
ethyl ester=10.33 x AUC0-6h of ethanol + 26.84. Also high correlation was found 360 
between the AUC0-6h of the ethanol concentrations with maximum 361 
concentrations of FAEES (palmitic acid: r=0.77 ([0.63, 0.87]; p<0.001); stearic 362 
acid: r=0.82 ([0.7, 0.89]; p<0.001); oleic acid: r=0.68 ([0.49, 0.81]; p<0.001); and 363 
linoleic acid r=0.62 ([0.4, 0.77]; p<0.001)). 364 
 365 
Discussion 366 
The administration of ethanol at low-moderate intoxicating doses (6-42g) to 367 
healthy volunteers produced detectable concentrations of ethanol non-oxidative 368 
metabolites (at least till 6h for several FAEES and ethanol doses and at least till 369 
24h for EtG). FAEES concentrations (AUC0-6h, Cmax) and EtG excretion (0-24h) 370 
16 
 
showed high correlation with the ethanol administered dose. Both increased 371 
with ethanol administered dose and their formation rates do not seem to follow 372 
a linear trend. On the other hand the relationship between AUC0-6h of ethanol 373 
and metabolites’ concentrations was linear. 374 
Ethanol concentrations  375 
Ethanol concentrations were similar to those obtained in previous studies 376 
(Rangno et al.,1981; Holford, 1987; Høiseth et al., 2007). Ethanol accumulation 377 
with dose (disproportionate increase in AUC) can be attributed to changes in 378 
hepatic extraction ratio with concentration and to capacity-limited elimination 379 
(Holford, 1987).  380 
Ethyl glucuronide 381 
EtG urinary excretion increased with the ethanol dose and as expected the 382 
highest recovery in urine was obtained with 42g. Although only <1% of the 383 
ethanol ingested is metabolized in humans to EtG (Politi et al., 2007) we have 384 
found a very high correlation between ethanol dose and EtG excretion. The 385 
disproportionate increase in EtG urinary excretion in relation to alcohol dose 386 
has been already described (Rosano and Lin, 2008; Jatlow et al., 2014). A 387 
similar trend in the relationship has been described in blood as the AUC of EtG 388 
was triplicated (2.43 vs. 8.58 mg x h/l) after just doubling the ethanol 389 
administered dose (0.5g/kg vs. 1g/kg) (Høiseth et al., 2010). Saturation of 390 
ethanol major metabolic pathway (ADH) and greater substrate availability for 391 
conjugation routes as the dose increases explains the results obtained (Rosano 392 
and Lin, 2008; Jatlow et al., 2014).  393 
Inter-individual variability found in EtG formation in subjects taking the same 394 
dose may be explained by genetics and nutritional factors. The glucuronidation 395 
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of ethanol through UDP-glucuronosyltransferases (UGT) is produced mainly by 396 
UGT1A1 and 2B7 (Politi et al., 2007). Additionally diet components like 397 
flavonoids may influence the conversion of ethanol to EtG through UGT 398 
competitive inhibition (Schwab and Skopp, 2014). EtG formation follows a 399 
Michaelis-Menten kinetics (also the ethanol oxidation to acetaldehyde by ADH) 400 
so ethanol concentrations available in each subject modulate the formation rate 401 
of EtG. Furthermore, the presence of polymorphisms coding the enzymes of 402 
ethanol oxidative metabolism could explain differences between subjects 403 
(Jatlow and O’Malley, 2010).  404 
Fatty acid ethyl esters 405 
FAEES determined in our study were those predominant in plasma after ethanol 406 
ingestion (Dan and Laposata, 1997; Politi et al., 2007). Inter-individual variability 407 
detected in FAEES concentrations was higher than for EtG. Individual 408 
differences can be attributed to the different activity of the enzymes responsible 409 
for FAAE synthesis or metabolism, but probably also to plasma triglyceride 410 
levels as a source of fatty acids for FAEES synthesis (Dan and Laposata, 1997; 411 
Soderberg et al., 1999). The concentration of saturated and monounsaturated 412 
FAEES showed a very high correlation with ethanol administered dose 413 
(Soderberg et al., 1999). On the other hand, the concentrations of the 414 
polyunsaturated linoleic acid ethyl ester showed a poorer correlation. The 415 
explanation can be related to the fact that linoleic acid is an essential fatty acid 416 
that is available only through diet, while palmitic, oleic and stearic acid are also 417 
obtained through metabolism. Breakfast 2h after ethanol administration can 418 
justify the small rise in linoleic acid ethyl ester concentrations at 4h. 419 
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The plasmatic FAEES limited detection period (6h) after ethanol doses 420 
compatible with social consumption, in comparison with 24h for EtG, and the 421 
long lasting elevations of FAEES that have been reported in heavy drinkers, 422 
due to diffusion from adipose tissue (Bisaga et al., 2005), makes urinary EtG 423 
more suitable to routinely monitor ethanol abstinence. 424 
To our knowledge this is the first study reporting the lack of linearity in the 425 
relationship between ethanol dose and FAEES plasma concentrations. The 426 
explanation could be the same than for EtG, a disproportionate increase in the 427 
amount of ethanol available for FAEES formation due to saturation of ethanol 428 
major metabolic pathway. In accordance to this data FAEES concentrations 429 
increased after the inhibition of the oxidative metabolism of ethanol (Best et al., 430 
2006).  431 
It should be noted that the non-linearity in the concentrations of both non-432 
oxidative metabolites of alcohol (urinary EtG and plasmatic FAEES) has been 433 
observed at relatively low doses of alcohol.  434 
Strengths and limitations 435 
The cross over design allowed the same subjects to be treated with at least two 436 
different doses. However, not all subjects received all doses and some 437 
comparisons were indirect. We enrolled only male volunteers for avoiding 438 
potential sex differences in ethanol and FAEES pharmacokinetics (FAEES 439 
formation can be two fold greater in man, according to Soderberg et al., 1999). 440 
Future studies with a larger sample size per dose should include women. The 441 
three day period between sessions was not enough to achieve a complete 442 
wash-out in some subjects although some FAEE could be endogenously 443 
formed. Furthermore higher doses of ethanol should be included to confirm the 444 
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trend observed in FAAE concentrations. Experimental sessions could not be 445 
planned long enough to provide a complete blood EtG pharmacokinetic profile. 446 
For this reason we decided to measure EtG only in urine, which was valuable to 447 
quantify the amount of ethanol excreted as EtG. 448 
Conclusion 449 
In conclusion, after administering low to moderate doses of ethanol to healthy 450 
male subjects the formation rate of EtG and FAEES does not seem to follow a 451 
linear trend and this observation should be taken into account when interpreting 452 
results in biological matrices in clinical and forensic settings. 453 
 454 
 455 
Figure legends 456 
Figure 1. Ethanol plasma concentrations. 457 
Ethanol plasma concentrations from 0 to 6h after ethanol administration. 458 
Figure 2. Ethyl glucuronide excretion. 459 
a Ethyl glucuronide excretion 0-24 h after ethanol administration. Values are 460 
expressed as mean ± standard deviation. 461 
b Effect of ethanol dose on percent metabolism to EtG. Individual data are 462 
presented. 463 
Figure 3. FAEES plasma concentrations. 464 
a Palmitic acid ethyl ester plasma concentrations from 0 to 6h after ethanol 465 
administration. 466 




c Stearic acid ethyl ester plasma concentrations from 0 to 6h after ethanol 469 
administration. 470 
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 625 
Supplementary material 626 
Fatty acids ethyl esters (FAEES) analysis 627 
FAEES plasma concentrations were analyzed by gas chromatography-mass 628 
spectrometry (GC/MS) based on a method previously described (Kulig et al., 629 
2006), with some modifications. One mL of each plasma sample was 630 
transferred to 12 mL glass tubes. Plasma calibration samples were prepared 631 
with blank plasma spiked at 2.5, 10, 50, 100, 200 and 300 ng/mL of each 632 
FAEES (Nu-Chek, MN, USA). Plasma and calibration samples were spiked with 633 
25 µL of internal standard solution (2.0 µg/mL heptanoic acid ethyl ester in 634 
methanol) and 50 µL of a 50 mM butylated hydroxytoluene (Sigma-Aldrich, MO, 635 
USA) solution in methanol. The plasma was extracted with 2 mL of acetone 636 
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(Merck, Germany). After vortex for a few seconds, the tubes were centrifuged 637 
(1700g, 5 min, room temperature). Next, the plasma was extracted with 6mL 638 
hexane (Merck, Germany) and placed in a rocking mixer over 20 min. After 639 
centrifugation (1700g, 5 min, room temperature) the acetone:hexane organic 640 
phase was separated to clean 12 mL glass tubes, placed in a water bath 641 
(<30ºC) and evaporated to dryness under a stream of nitrogen. The extracts 642 
were reconstituted in 1 mL hexane and applied to an aminopropyl solid phase 643 
extraction column (LRC Bond Elut NH2, Agilent, CA, USA), previously 644 
conditioned with 2 mL hexane. The hexane eluates were collected in 12 mL 645 
glass tubes and an additional 1mL pure hexane was applied to the columns and 646 
collected. The tubes were placed in a water bath (<30ºC) and the hexane eluate 647 
was evaporated to dryness under a stream of nitrogen. The extracts were 648 
reconstituted in 100 µL hexane and transferred to vials. Three µL of extract 649 
were injected into the GC/MS system (Agilent 5973, CA, United States) in the 650 
split mode with a split ratio 1:10. Chromatographic separation of FAEES was 651 
achieved with a 100% methylsilicone column (Zebron ZB-1, 15m length, 250µm 652 
diameter, 0.25µm film thickness) at 1 mL/min helium flow. The mass detector 653 
transfer line heater and the injection port were set at 280ºC. The oven 654 
temperature ramp was as follows: initial condition 150ºC for 2 min, then a ramp 655 
at 15ºC/min to 295, and finally the temperature was kept at 295ºC for 4 min with 656 
a total run time of 15.7 min. Quantification was done by single ion monitoring 657 
(SIM) with the following m/z ions for each FAEES: m/z 88, m/z 241 and m/z 284 658 
for palmitic acid ethyl ester, m/z 222, m/z 264 and m/z 180 for oleic acid ethyl 659 
ester, m/z 101, m/z 269 and m/z 312 for stearic acid ethyl ester, m/z 306 and 660 
m/z 261 for linoleic acid ethyl ester, and m/z 88, m/z 157 and m/z 255 for 661 
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heptanoic acid ethyl ester. The method was validated in-house. Intra-day and 662 
inter-day accuracy and precision were <15% for quality control spiked plasma 663 
samples. The lower limit of quantification (LLOQ) for palmitic, stearic, oleic and 664 
linoleic acid ethyl esters were 2.5, 3.5, 3.0 and 2.5 ng/mL, respectively. 665 
 666 
Analysis of ethylglucuronide (EtG) by LC/MS/MS 667 
Ethyl Glucuronide was measured with liquid chromatography-mass 668 
spectrometry (LC/MS) using a dilute and shoot approach. The LLOQ was 0.41 669 
µg/mL. Briefly, 50 µL of centrifuged urine samples were spiked with internal 670 
standards (EtG-d5 and EtS-d5). Thereafter samples were diluted with 900 µL of 671 
0.1% aqueous formic acid solution, and 10 µL were injected into the LC-MS/MS 672 
system. The LC-MS/MS system consisted of an Agilent 1200 series HPLC 673 
system (Agilent Technologies) coupled to a 6410 Triple Quadrupole LC-MS 674 
(Agilent Technologies) mass spectrometer with an electrospray interface. 675 
Chromatographic separation was achieved on an Acquity HSS T3 column (2.1 x 676 
100 mm, 1.8 μm particle size) (Waters Corp.) at 40°C. The electrospray ion 677 
source was set on the negative ionization mode. The mass spectrometry 678 
detection was done by single reaction monitoring (SRM). Quantification was 679 
calculated with the slope (s), intercept and correlation coefficient (r) by 680 
weighting (1/x) least-squares linear regression of the peak area ratio 681 
(analyte/IS) versus the concentration of the standard. 682 
 683 
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